Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.
Trial locations(8 sites)
China
Nanfang Hospital Southern Medical University, Guangzhou, Guangdong The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Shenzhen Pingshan District People's Hospital, Shenzhen, Guangdong The Second Affiliated Hospital The Chinese University of Hong Kong, Shenzhen & Longgang District People's Hospital of Shenzhen, Shenzhen, Guangdong Yangjiang People's Hospital of Guangdong Medical University, Yangjiang, Guangdong Zhuhai People's Hospital (Zhuhai Hospital Affiliated to Jinan University), Zhuhai, Guangdong Prince of Wales Hospital, Hong Kong, Hong Kong SAR